- 31 May |Post Prelims Meet with Ayush Sir | Offline Session to discuss the Post-Prelims agenda | ForumIAS Click Here to register for the event →
- 02 June |Open Session - The PSIR Mark Improvement by Aman Aloon (AIR 295, UPSC CSE 2025)|Click Here to register for the event →
- 04 June | Open Orientation for GSAP 2026| Click Here to register →
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
Source: The post is based on the article “India’s first mRNA vaccine against Omicron approved” published in The Hindu on 21st June 2023
What is the News?
India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM has been approved under emergency use guidelines by the Drug Controller General of India.
What is GEMCOVAC-OM?
GEMCOVAC-OM is India’s first indigenous mRNA vaccine for the Omicron variant of the novel coronavirus.
Developed by: Pune-based Gennova Biopharmaceuticals Ltd
Eligibility: Those who are 18 years of age and older can take the vaccine as a booster dose. This can be administered safely to individuals who have received two doses of either Covaxin or Covishield.
Features: It is a thermo-stable vaccine, which does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India.
– It is delivered intra-dermally using a needle-free injection device system.
– When administered intradermally in participants as a booster, it generated significantly higher immune responses.
